Cholangiocarcinoma  >>  oxaliplatin  >>  Phase 1
Welcome,         Profile    Billing    Logout  

11 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
PROMIFOX, NCT04729205: Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Folfox in Patients With GI Malignancies

Terminated
1b
9
RoW
Promitil, Pegylated Liposomal Mitomycin-C Lipid-based Prodrug, Folfox
Lipomedix Pharmaceuticals Inc.
Cancer, Gastro-Intestinal Intraepithelial Neoplasia
09/23
09/23
NCT00003427: Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer

Completed
1
36
US
irinotecan hydrochloride, oxaliplatin
Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI)
Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer, Pancreatic Cancer, Small Intestine Cancer
04/02
04/02
NCT00266097: Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer

Checkmark Data
May 2012 - May 2012: Data
Completed
1
23
US
erlotinib hydrochloride, gemcitabine hydrochloride, oxaliplatin, radiation therapy, Oxaliplatin
UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI)
Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Pancreatic Cancer
03/09
09/11
NCT00987766: Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer

Completed
1
28
US
erlotinib hydrochloride, gemcitabine hydrochloride, oxaliplatin, laboratory biomarker analysis
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Pancreatic Cancer, Periampullary Adenocarcinoma, Small Intestine Cancer
07/13
10/16
NCT01643499: Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies

Completed
1
79
US
oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, laboratory biomarker analysis
University of Chicago, National Cancer Institute (NCI)
Acinar Cell Adenocarcinoma of the Pancreas, Adenocarcinoma of the Gallbladder, Adenocarcinoma of Unknown Primary, Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Diffuse Adenocarcinoma of the Stomach, Duct Cell Adenocarcinoma of the Pancreas, Intestinal Adenocarcinoma of the Stomach, Localized Unresectable Adult Primary Liver Cancer, Metastatic Carcinoma of Unknown Primary, Metastatic Extrahepatic Bile Duct Cancer, Mixed Adenocarcinoma of the Stomach, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Newly Diagnosed Carcinoma of Unknown Primary, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage III Pancreatic Cancer, Stage IIIA Colon Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Gastric Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Gastric Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Gastric Cancer, Stage IIIC Rectal Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer, Stage IVA Colon Cancer, Stage IVA Gallbladder Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Gallbladder Cancer, Stage IVB Rectal Cancer, Unresectable Extrahepatic Bile Duct Cancer
08/16
07/19
NCT02648711: Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors

Checkmark From trial evaluating weekly dosing of CRLX101 with or without Avastin in solid tumors at ESMO 2016
Sep 2016 - Sep 2016: From trial evaluating weekly dosing of CRLX101 with or without Avastin in solid tumors at ESMO 2016
Terminated
1
41
US
CRLX101, NLG207, Bevacizumab, Avastin, mFOLFOX6, oxaliplatin, leucovorin, 5FU
NewLink Genetics Corporation
Solid Tumors
10/17
05/18
SIRINOX, NCT02387138: A Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan

Completed
1
24
Europe
S-1, Irinotecan, Oxaliplatin, G-csf
Institut du Cancer de Montpellier - Val d'Aurelle
Digestive Cancer
06/18
09/18
NCT01525069: Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma

Terminated
1
27
US
Floxuridine, 5-FUDR, FdUrD, floxuridin, fluorodeoxyuridine, fluoruridine deoxyribose, FUdR, Dexamethasone, Aeroseb-Dex, Decaderm, Decadron, Decaspray, DM, DXM, Gemcitabine, dFdC, dFdCyd, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar, LY-188011, Oxaliplatin, 1-OHP, Dacotin, Dacplat, diaminocyclohexane oxalatoplatinum, Eloxatin, L-OHP
Washington University School of Medicine
Cholangiocarcinoma, Liver Neoplasms
08/18
08/22
NCT04164069: Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

Active, not recruiting
1
9
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, Folinic acid, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, citrovorum factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Quality-of-Life Assessment, Quality of Life Assessment
Anne Noonan
Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage II Colon Cancer, Stage II Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Esophageal Cancer, Pancreatic Cancer, Bile Duct Cancer, Gastric Cancer, Gall Bladder Cancer, Small Bowel Adenocarcinoma
06/23
12/23
CCGLC-007, NCT05533892: Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC

Recruiting
1
30
RoW
Nocardia rubra cell wall skeleton, N-CWS, Hepatic arterial infusion chemotherapy, HAIC, Lenvatinib, JieLiEn, Tislelizumab, BaiZeAn
Wan-Guang Zhang, Chinese Cooperative Group of Liver Cancer (CCGLC), Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, M&R Pharm, Geneplus-Beijing Co. Ltd., Yuce Biotechnology Co., Ltd., Geneis, Simcere Pharmaceutical Co., Ltd, BeiGene, Haplox Biotechnology Co., Ltd.
Hepatocellular Carcinoma
08/24
02/25
I-FLOAT, NCT04361708: Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

Recruiting
1
54
US
Oxaliplatin, Docetaxel, Leucovorin, Irinotecan, 5-Fluorouracil
University of Chicago
Pancreatic Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Adenocarcinoma
06/25
05/27

Download Options